tetano
Editor, Senior Moderator
mBio
. 2023 Feb 23;e0337922.
doi: 10.1128/mbio.03379-22. Online ahead of print.
Reduced Mortality among COVID-19 ICU Patients after Treatment with HemoClear Convalescent Plasma in Suriname
R Bihariesingh-Sanchit[SUP] 1 2 [/SUP], R Bansie[SUP] 3 [/SUP], N Ramdhani[SUP] 1 [/SUP], R Mangroo[SUP] 3 [/SUP], D Bustamente[SUP] 1 [/SUP], E Diaz[SUP] 2 [/SUP], C Fung A Foek[SUP] 1 [/SUP], I Thakoer[SUP] 4 [/SUP], S Vreden[SUP] 3 [/SUP], Z Choudhry[SUP] 5 [/SUP], A B van 't Wout[SUP] 6 7 [/SUP], D A Diavatopoulos[SUP] 8 9 [/SUP], A P Nierich[SUP] 10 11 [/SUP]
Affiliations
Abstract
Convalescent plasma is a promising therapy for coronavirus disease 2019 (COVID-19), but its efficacy in intensive care unit (ICU) patients in low- and middle-income country settings such as Suriname is unknown. Bedside plasma separation using the HemoClear device made convalescent plasma therapy accessible as a treatment option in Suriname. Two hundred patients with severe SARS-CoV-2 infection requiring intensive care were recruited. Fifty eight patients (29%) received COVID-19 convalescent plasma (CCP) treatment in addition to standard of care (SOC). The CCP treatment and SOC groups were matched by age, sex, and disease severity scores. Mortality in the CCP treatment group was significantly lower than that in the SOC group (21% versus 39%; Fisher's exact test P = 0.0133). Multivariate analysis using ICU days showed that CCP treatment reduced mortality (hazard ratio
, 0.35; 95% confidence interval [CI], 0.18 to 0.66; P = 0.001), while complication of acute renal failure (creatinine levels, >110 mol/L; HR, 4.45; 95% CI, 2.54 to 7.80; P < 0.0001) was independently associated with death. Decrease in chest X-ray score in the CCP treatment group (median -3 points, interquartile range [IQR] -4 to -1) was significantly greater than that in the SOC group (median -1 point, IQR -3 to 1, Mann-Whitney test P = 0.0004). Improvement in the PaO[SUB]2[/SUB]/FiO[SUB]2[/SUB] ratio was also significantly greater in the CCP treatment group (median 83, IQR 8 to 140) than in the SOC group (median 35, IQR -3 to 92, Mann-Whitney P = 0.0234). Further research is needed for HemoClear-produced CCP as a therapy for SARS-CoV-2 infection together with adequately powered, randomized controlled trials. IMPORTANCE This study compares mortality and other endpoints between intensive care unit COVID-19 patients treated with convalescent plasma plus standard of care (CCP), and a control group of patients hospitalized in the same medical ICU facility treated with standard of care alone (SOC) in a low- and middle-income country (LMIC) setting using bedside donor whole blood separation by gravity (HemoClear) to produce the CCP. It demonstrates a significant 65% survival improvement in HemoClear-produced CCP recipients (HR, 0.35; 95% CI, 0.19 to 0.66; P = 0.001). Although this is an exploratory study, it clearly shows the benefit of using the HemoClear-produced CCP in ICU patients in the Suriname LMIC setting. Additional studies could further substantiate our findings and their applicability for both LMICs and high-income countries and the use of CCP as a prepared readiness method to combat new viral pandemics.
Keywords: COVID-19; HemoClear; ICU; SARS-CoV-2; convalescent plasma; mortality.
. 2023 Feb 23;e0337922.
doi: 10.1128/mbio.03379-22. Online ahead of print.
Reduced Mortality among COVID-19 ICU Patients after Treatment with HemoClear Convalescent Plasma in Suriname
R Bihariesingh-Sanchit[SUP] 1 2 [/SUP], R Bansie[SUP] 3 [/SUP], N Ramdhani[SUP] 1 [/SUP], R Mangroo[SUP] 3 [/SUP], D Bustamente[SUP] 1 [/SUP], E Diaz[SUP] 2 [/SUP], C Fung A Foek[SUP] 1 [/SUP], I Thakoer[SUP] 4 [/SUP], S Vreden[SUP] 3 [/SUP], Z Choudhry[SUP] 5 [/SUP], A B van 't Wout[SUP] 6 7 [/SUP], D A Diavatopoulos[SUP] 8 9 [/SUP], A P Nierich[SUP] 10 11 [/SUP]
Affiliations
- PMID: 36815780
- DOI: 10.1128/mbio.03379-22
Abstract
Convalescent plasma is a promising therapy for coronavirus disease 2019 (COVID-19), but its efficacy in intensive care unit (ICU) patients in low- and middle-income country settings such as Suriname is unknown. Bedside plasma separation using the HemoClear device made convalescent plasma therapy accessible as a treatment option in Suriname. Two hundred patients with severe SARS-CoV-2 infection requiring intensive care were recruited. Fifty eight patients (29%) received COVID-19 convalescent plasma (CCP) treatment in addition to standard of care (SOC). The CCP treatment and SOC groups were matched by age, sex, and disease severity scores. Mortality in the CCP treatment group was significantly lower than that in the SOC group (21% versus 39%; Fisher's exact test P = 0.0133). Multivariate analysis using ICU days showed that CCP treatment reduced mortality (hazard ratio
, 0.35; 95% confidence interval [CI], 0.18 to 0.66; P = 0.001), while complication of acute renal failure (creatinine levels, >110 mol/L; HR, 4.45; 95% CI, 2.54 to 7.80; P < 0.0001) was independently associated with death. Decrease in chest X-ray score in the CCP treatment group (median -3 points, interquartile range [IQR] -4 to -1) was significantly greater than that in the SOC group (median -1 point, IQR -3 to 1, Mann-Whitney test P = 0.0004). Improvement in the PaO[SUB]2[/SUB]/FiO[SUB]2[/SUB] ratio was also significantly greater in the CCP treatment group (median 83, IQR 8 to 140) than in the SOC group (median 35, IQR -3 to 92, Mann-Whitney P = 0.0234). Further research is needed for HemoClear-produced CCP as a therapy for SARS-CoV-2 infection together with adequately powered, randomized controlled trials. IMPORTANCE This study compares mortality and other endpoints between intensive care unit COVID-19 patients treated with convalescent plasma plus standard of care (CCP), and a control group of patients hospitalized in the same medical ICU facility treated with standard of care alone (SOC) in a low- and middle-income country (LMIC) setting using bedside donor whole blood separation by gravity (HemoClear) to produce the CCP. It demonstrates a significant 65% survival improvement in HemoClear-produced CCP recipients (HR, 0.35; 95% CI, 0.19 to 0.66; P = 0.001). Although this is an exploratory study, it clearly shows the benefit of using the HemoClear-produced CCP in ICU patients in the Suriname LMIC setting. Additional studies could further substantiate our findings and their applicability for both LMICs and high-income countries and the use of CCP as a prepared readiness method to combat new viral pandemics.
Keywords: COVID-19; HemoClear; ICU; SARS-CoV-2; convalescent plasma; mortality.